We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bivictrix Therapeutics Plc | LSE:BVX | London | Ordinary Share | GB00BNXH3K91 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -4.26% | 11.25 | 10.50 | 12.00 | 11.75 | 11.25 | 11.75 | 34,569 | 15:25:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -2.5M | -0.0303 | -3.71 | 9.28M |
TIDMBVX
RNS Number : 1106E
BiVictriX Therapeutics PLC
09 March 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
9 March 2022
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
Director Dealing
Alderley Park, 9 March 2022 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces the following dealing in the Company's ordinary shares of 1 pence each ("Ordinary Shares").
On 8 March 2022, 100,000 Ordinary Shares at a price of 22.25 pence each were purchased by Iain Ross, Chairman of the Company, through his self-invested personal pension (SIPP).
Following this purchase, Mr Ross is benefically interested in 400,000 Ordinary Shares representing 0.61 per cent of the Company's total issued share capital.
-Ends-
For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Email: info@bivictrix.com Iain Ross, Chairman SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: +44 (0) 20 3470 0470 David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: +44 (0) 20 7886 2500 Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Mary-Jane Elliott, Genevieve Wilson, Tel: +44 (0) 20 3709 5700 Alex Gunter Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.
BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Iain Ross ------------------------------- -------------------------------------- 2. Reason for the Notification ----------------------------------------------------------------------- a) Position/status Non-Executive Chairman ------------------------------- -------------------------------------- b) Initial notification/Amendment Initial notification ------------------------------- -------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------- a) Name BiVictriX Therapeutics plc ------------------------------- -------------------------------------- b) LEI 213800ZI85IZNA6N3L53 ------------------------------- -------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------- a) Description of Ordinary Shares of 1 pence each the Financial GB00BNXH3K91 instrument, type of instrument Identification code ------------------------------- -------------------------------------- b) Nature of the Purchase of Ordinary Shares via transaction SIPP ------------------------------- -------------------------------------- c) Price(s) and Price(s) Volume(s) volume(s) 22.25 p 100,000 ---------- ------------------------------- -------------------------------------- d) Aggregated information: Price(s) Volume(s) * Aggregated volume 22.25p 100,000 ---------- * Price ------------------------------- -------------------------------------- e) Date of the transaction 8 March 2022 ------------------------------- -------------------------------------- f) Place of the AIM, London Stock Exchange transaction ------------------------------- --------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDDGDXCBGDGDI
(END) Dow Jones Newswires
March 09, 2022 02:01 ET (07:01 GMT)
1 Year Bivictrix Therapeutics Chart |
1 Month Bivictrix Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions